What pharmaceutical company makes Taxotere?
Taxotere is a chemotherapy drug made by Sanofi-Aventis. It belongs to a drug class called taxanes.
What is the brand name for docetaxel?
Taxotere is the trade name for docetaxel. In some cases, health care professionals may use the trade name taxotere when referring to the generic drug name docetaxel. Drug type: Docetaxel is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.
How much does docetaxel cost?
The cost for docetaxel intravenous solution (20 mg/mL) is around $32 for a supply of 1 milliliter(s), depending on the pharmacy you visit….Intravenous Solution.
| Quantity | Per unit | Price |
|---|---|---|
| 1 milliliter | $31.94 – $34.45 | $31.94 – $34.45 |
| 4 milliliters | $22.27 – $22.97 | $89.06 – $91.89 |
Is docetaxel platinum based chemo?
We planned a phase II trial in order to asses objective activity and toxicity of docetaxel administered as a single agent, at a dose of 80 mg/m2 every 21 days, in patients with squamous-cell head and neck cancer, relapsed after treatment with a platinum-based regimen….
| Median age, years (range) | 60 (40–75) |
|---|---|
| Dysphagia | 5 |
Is docetaxel the same as Taxol?
According to an article recently published in the Annals of Oncology, longer follow-up results indicate that the chemotherapy agent Taxotere® (docetaxel) remains superior to the chemotherapy agent Taxol® (paclitaxel) in the treatment of metastatic breast cancer among patients who have received prior therapy with …
Do you lose your hair with docetaxel?
Conclusions: Both docetaxel and paclitaxel may cause permanent scalp hair loss, but it is significantly more prevalent with docetaxel compared with paclitaxel.
Is there a generic for Xtandi?
Enzalutamide is the generic name for the trade name drug Xtandi®. In some cases, health care professionals may use the trade name Xtandi® when referring to the generic drug name enzalutamide.
How long can you stay on Xtandi?
How long does Xtandi extend life? In the AFFIRM trial, treatment with Xtandi extended life by almost 5 months. Treatment with Xtandi resulted in a median overall survival time of 18.4 months (95% CI 17.3 to not yet reached) compared with 13.6 months (95% CI 11.3 to 15.8) in the placebo recipients (p<0.001).